Literature DB >> 29449336

Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients.

Nigel Mackman1, Henri M H Spronk2, George A Stouffer2, Hugo Ten Cate2.   

Abstract

Entities:  

Keywords:  anticoagulants; apolipoprotein; coronary artery disease; myocardial infarction; patients

Mesh：

Substances：

Year:  2018        PMID： 29449336      PMCID： PMC5978740          DOI： 10.1161/ATVBAHA.117.310048

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN： 1079-5642            Impact factor:   8.311


× No keyword cloud information.
  52 in total

1.  Rivaroxaban in patients with a recent acute coronary syndrome.

Authors:  Jessica L Mega; Eugene Braunwald; Stephen D Wiviott; Jean-Pierre Bassand; Deepak L Bhatt; Christoph Bode; Paul Burton; Marc Cohen; Nancy Cook-Bruns; Keith A A Fox; Shinya Goto; Sabina A Murphy; Alexei N Plotnikov; David Schneider; Xiang Sun; Freek W A Verheugt; C Michael Gibson
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

2.  Platelet P-selectin facilitates atherosclerotic lesion development.

Authors:  Peter C Burger; Denisa D Wagner
Journal:  Blood       Date:  2002-12-12       Impact factor: 22.113

3.  ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC).

Authors:  Michal Tendera; Victor Aboyans; Marie-Louise Bartelink; Iris Baumgartner; Denis Clément; Jean-Philippe Collet; Alberto Cremonesi; Marco De Carlo; Raimund Erbel; F Gerry R Fowkes; Magda Heras; Serge Kownator; Erich Minar; Jan Ostergren; Don Poldermans; Vincent Riambau; Marco Roffi; Joachim Röther; Horst Sievert; Marc van Sambeek; Thomas Zeller
Journal:  Eur Heart J       Date:  2011-08-26       Impact factor: 29.983

4.  Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice.

Authors:  M Dewerchin; Z Liang; L Moons; P Carmeliet; F J Castellino; D Collen; E D Rosen
Journal:  Thromb Haemost       Date:  2000-02       Impact factor: 5.249

Review 5.  New developments in anticoagulants: Past, present and future.

Authors:  Jeffrey I Weitz; Job Harenberg
Journal:  Thromb Haemost       Date:  2017-06-08       Impact factor: 5.249

6.  Long-term use of ticagrelor in patients with prior myocardial infarction.

Authors:  Marc P Bonaca; Deepak L Bhatt; Marc Cohen; Philippe Gabriel Steg; Robert F Storey; Eva C Jensen; Giulia Magnani; Sameer Bansilal; M Polly Fish; Kyungah Im; Olof Bengtsson; Ton Oude Ophuis; Andrzej Budaj; Pierre Theroux; Mikhail Ruda; Christian Hamm; Shinya Goto; Jindrich Spinar; José Carlos Nicolau; Robert G Kiss; Sabina A Murphy; Stephen D Wiviott; Peter Held; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2015-03-14       Impact factor: 91.245

Review 7.  Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants.

Authors:  Noel C Chan; John W Eikelboom; Jeffrey I Weitz
Journal:  Circ Res       Date:  2016-04-29       Impact factor: 17.367

8.  The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice.

Authors:  Illkyu-O Lee; Mario T Kratz; Stephan H Schirmer; Magnus Baumhäkel; Michael Böhm
Journal:  J Pharmacol Exp Ther       Date:  2012-07-25       Impact factor: 4.030

9.  Prothrombin deficiency results in embryonic and neonatal lethality in mice.

Authors:  W Y Sun; D P Witte; J L Degen; M C Colbert; M C Burkart; K Holmbäck; Q Xiao; T H Bugge; S J Degen
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

10.  Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice.

Authors:  Simon Pingel; Vedat Tiyerili; Jens Mueller; Nikos Werner; Georg Nickenig; Cornelius Mueller
Journal:  Arch Med Sci       Date:  2014-02-23       Impact factor: 3.318
View more
  5 in total

1.  Protease Activity in Vascular Disease.

Authors:  Megan A Slack; Scott M Gordon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-09-25       Impact factor: 8.311

2.  The age-specific prognostic impact of the platelet-to-lymphocyte ratio on long-term outcome after acute coronary syndrome.

Authors:  Niema Kazem; Felix Hofer; Lorenz Koller; Andreas Hammer; Thomas M Hofbauer; Christian Hengstenberg; Alexander Niessner; Patrick Sulzgruber
Journal:  Eur Heart J Open       Date:  2021-10-27

3.  Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease.

Authors:  Kong-Xiang Zhu; Pei-Yuan Song; Mu-Peng Li; Yin-Xiao Du; Qi-Lin Ma; Li-Ming Peng; Xiao-Ping Chen
Journal:  Eur J Clin Pharmacol       Date:  2020-10-21       Impact factor: 2.953

4.  Saccharides from Arctium lappa L. root reduce platelet activation and thrombus formation in a laser injury thrombosis mouse model.

Authors:  Yongjuan Ruan; Yanzhong Ding; Xiaowei Li; Chunyang Zhang; Mengyu Wang; Mengduan Liu; Lu Wang; Junhui Xing; Liang Hu; Xiaoyan Zhao; Zhongren Ding; Jianzeng Dong; Yangyang Liu
Journal:  Exp Ther Med       Date:  2022-03-22       Impact factor: 2.447

5.  Knowledge, Attitude, and Practice Toward Cardiovascular Diseases in the Lebanese Population.

Authors:  Marc Machaalani; Battoul Fakhry; Maisoon Zwaideh; Karl Mendelek; Nadine Mahmoud; Talal Hammoud; Mirna N Chahine
Journal:  Glob Heart       Date:  2022-07-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.